Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Post Marketing Surveillance Study For Observing Safety And Efficacy Of Lyrica

This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.

continuous patients with target disorders in collaborating institutions

Inclusion Criteria:

• Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion Criteria:

• Non-consenting
• Hypersensitivity to the active substance or to any of the excipients
• galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.